Lonza, Moderna Expand Collaboration on Production of Covid-19 Vaccine Drug Substance

By Olivia Bugault

Lonza Group AG said Wednesday that it will be further collaborating with Moderna Inc. to extend the production of the drug substance for the Covid-19 vaccine made by the U.S. biotechnology company.

Under the deal, Lonza will install a new production line in Geleen, the Netherlands, that will contribute to supply up to 300 million additional doses of the vaccine a year, the Swiss life-sciences company said. Operations on the new manufacturing line should start by the end of this year, it said.

"In May 2020, Lonza and Moderna announced a ten-year strategic collaboration agreement to enable the manufacture of Moderna's Covid-19 vaccine and additional Moderna products in the future," Lonza said. Since May of last year, Lonza has already installed several production lines in Switzerland and the U.S., it said.

Write to Olivia Bugault at [e-mail]

(END) Dow Jones Newswires

06-02-21 0144ET